These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 26558403)
1. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Rolla S; Alchera E; Imarisio C; Bardina V; Valente G; Cappello P; Mombello C; Follenzi A; Novelli F; Carini R Clin Sci (Lond); 2016 Feb; 130(3):193-203. PubMed ID: 26558403 [TBL] [Abstract][Full Text] [Related]
2. Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity. Alchera E; Rolla S; Imarisio C; Bardina V; Valente G; Novelli F; Carini R Transl Res; 2017 Apr; 182():75-87. PubMed ID: 28011152 [TBL] [Abstract][Full Text] [Related]
3. NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses. Locatelli I; Sutti S; Vacchiano M; Bozzola C; Albano E Clin Sci (Lond); 2013 Feb; 124(4):279-87. PubMed ID: 22970906 [TBL] [Abstract][Full Text] [Related]
4. 3, 3'-Diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance. Liu Y; She W; Wang F; Li J; Wang J; Jiang W Int Immunopharmacol; 2014 Dec; 23(2):489-98. PubMed ID: 25281898 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374 [TBL] [Abstract][Full Text] [Related]
7. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Maina V; Sutti S; Locatelli I; Vidali M; Mombello C; Bozzola C; Albano E Clin Sci (Lond); 2012 Jun; 122(11):545-53. PubMed ID: 22142284 [TBL] [Abstract][Full Text] [Related]
8. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Sutti S; Jindal A; Locatelli I; Vacchiano M; Gigliotti L; Bozzola C; Albano E Hepatology; 2014 Mar; 59(3):886-97. PubMed ID: 24115128 [TBL] [Abstract][Full Text] [Related]
9. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH). Jindal A; Bruzzì S; Sutti S; Locatelli I; Bozzola C; Paternostro C; Parola M; Albano E Exp Mol Pathol; 2015 Aug; 99(1):155-62. PubMed ID: 26112094 [TBL] [Abstract][Full Text] [Related]
10. Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver. Rau M; Schilling AK; Meertens J; Hering I; Weiss J; Jurowich C; Kudlich T; Hermanns HM; Bantel H; Beyersdorf N; Geier A J Immunol; 2016 Jan; 196(1):97-105. PubMed ID: 26621860 [TBL] [Abstract][Full Text] [Related]
11. CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis. Sutti S; Locatelli I; Bruzzì S; Jindal A; Vacchiano M; Bozzola C; Albano E Clin Sci (Lond); 2015 Nov; 129(9):797-808. PubMed ID: 26253086 [TBL] [Abstract][Full Text] [Related]
12. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126 [TBL] [Abstract][Full Text] [Related]
13. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. Kroy DC; Schumacher F; Ramadori P; Hatting M; Bergheim I; Gassler N; Boekschoten MV; Müller M; Streetz KL; Trautwein C J Hepatol; 2014 Oct; 61(4):883-90. PubMed ID: 24845607 [TBL] [Abstract][Full Text] [Related]
14. Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis. González-Rodríguez Á; Valdecantos MP; Rada P; Addante A; Barahona I; Rey E; Pardo V; Ruiz L; Laiglesia LM; Moreno-Aliaga MJ; García-Monzón C; Sánchez A; Valverde ÁM Mol Metab; 2018 Jan; 7():132-146. PubMed ID: 29126873 [TBL] [Abstract][Full Text] [Related]
15. Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. Ye D; Yang K; Zang S; Lin Z; Chau HT; Wang Y; Zhang J; Shi J; Xu A; Lin S; Wang Y J Hepatol; 2016 Nov; 65(5):988-997. PubMed ID: 27266617 [TBL] [Abstract][Full Text] [Related]
16. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Gao Y; Liu Y; Yang M; Guo X; Zhang M; Li H; Li J; Zhao J Oncotarget; 2016 Jun; 7(23):33649-61. PubMed ID: 27172901 [TBL] [Abstract][Full Text] [Related]
18. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. Tosello-Trampont AC; Landes SG; Nguyen V; Novobrantseva TI; Hahn YS J Biol Chem; 2012 Nov; 287(48):40161-72. PubMed ID: 23066023 [TBL] [Abstract][Full Text] [Related]
19. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin. Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616 [TBL] [Abstract][Full Text] [Related]
20. Regulation of gut inflammation and th17 cell response by interleukin-21. Fina D; Sarra M; Fantini MC; Rizzo A; Caruso R; Caprioli F; Stolfi C; Cardolini I; Dottori M; Boirivant M; Pallone F; Macdonald TT; Monteleone G Gastroenterology; 2008 Apr; 134(4):1038-48. PubMed ID: 18395085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]